Media & Advertising
Glaxosmithkline Plc and Genmab A/S Announce Positive Top-Line Results From Pivotal
Have an interest in this Story?
Sign Up for Real-Time email updates
May 29, 2013
6:16pm BST Genmab A/S and Glaxosmithkline Plc announced that their Phase III study of ARZERRA (ofatumumab) in combination with chlorambucil versus chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL) met its primary endpoint of progression free survival (PFS) a...
Read Full Article
Leave a Comment:
You must be logged in to leave a comment
Most Read Biotech Articles
The Approval Of The First Biosimilar Monoclonal Antibody In Europe Has Major Implications
Camber Corporation announces the promotion of John Lord to President of the company.
olloclip® Introduces the Macro 3-IN-1 Clip-On Photo Lens for iPhone and iPod touch
- Digital Photography Now
Ventana receives FDA clearance for Estrogen Receptor (ER) Image Analysis and Digital
Divestitures, Event Participations, Patents, Clinical Studies and Trials - Research
- KPHO Phoenix
Sergio Waldeck, MBA
Director of Financial Planning and Analysis
View more profiles
Access dozens of premium and subscriptions sites
Build a News Circle
Get News Briefings
Congoo News Home
Get the Netpass
Copyright ©2013 Congoo.com. All Rights Reserved.